RxDoctor Payments Data

Zoe Robbins

Psychiatric/Mental Health · Sandy, UTNPI 1134321508

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 26 payments — averaging $45.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$284
  • AbbVie$216
  • Neurocrine Biosciences, Inc.$215
  • Alkermes, Inc.$156
  • Axsome Therapeutics, Inc.$122
  • Johnson & Johnson$118
  • plus $80 from 2 others

What the payments were for

  • Food & beverage$1,16398%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,191 in reported general payments places this provider in the 65th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$6,981
Medicare patients
20
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate22$79,489
VraylarCariprazine Hcl13$24,256
FetzimaLevomilnacipran Hcl15$6,525
Clozapine39$2,371
Aripiprazole17$1,634
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$867
Prazosin Hcl32$732
Methylphenidate Hcl12$483
Clonazepam42$473
Buspirone Hcl28$473
Trazodone Hcl18$358
Bupropion XlBupropion Hcl11$354
Bupropion Hcl SrBupropion Hcl13$330
Citalopram HbrCitalopram Hydrobromide26$323
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$118$79,48922 claims
AbbVieVraylar, Fetzima$216$30,78228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →